Arovella Therapeutics Limited (E4NA) Ratios
Arovella Therapeutics Limited Ratios
DE:E4NA's free cash flow for Q4 2026 was $-5.19M. For the 2026 fiscal year, DE:E4NA's free cash flow was increased by $8.90K and operating cash flow was $-5.20M. See a summary of the company’s cash flow.
| Ratios | Jun 26 | Jun 25 | Jun 24 | Jun 23 | Jun 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 17.51 | 14.18 | 6.45 | 3.10 | 4.37 |
| Quick Ratio | 17.51 | 14.18 | 6.45 | 3.10 | 4.37 |
| Cash Ratio | 17.15 | 13.99 | 6.23 | 3.08 | 4.02 |
| Solvency Ratio | -7.93 | -4.86 | -4.23 | -5.53 | -5.06 |
| Operating Cash Flow Ratio | -8.25 | -4.64 | -3.39 | -3.80 | -4.15 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | -5586.67 |
| Net Current Asset Value | $ 13.80M | $ 19.65M | $ 11.10M | $ 3.53M | $ 4.99M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.03 | 0.02 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.04 | 0.02 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.04 | 0.02 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.06 | 1.08 | 1.18 | 1.45 | 1.21 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | -1007.35 | -450.98 | -40.21 |
| Interest Coverage Ratio | 0.00 | 0.00 | -1252.61 | -468.26 | -38.99 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | 1.29 | 1.88 | 1.20 | 0.48 | 0.75 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 100.00% | -152.82% | -739.07% | 30.00% |
| EBIT Margin | 0.00% | -8237.35% | -62779.56% | -2761.64% | -2848.41% |
| EBITDA Margin | 0.00% | -8158.46% | -62526.75% | -2555.39% | -2661.97% |
| Operating Profit Margin | 0.00% | -8237.35% | -63595.65% | -2385.02% | -2566.71% |
| Pretax Profit Margin | 0.00% | -5521.45% | -51447.26% | -2766.73% | -2914.23% |
| Net Profit Margin | 0.00% | -5521.45% | -51447.26% | -2508.35% | -2914.23% |
| Continuous Operations Profit Margin | 0.00% | -3092.58% | -51447.26% | -2508.35% | -2914.23% |
| Net Income Per EBT | 66.41% | 100.00% | 100.00% | 90.66% | 100.00% |
| EBT Per EBIT | 92.87% | 67.03% | 80.90% | 116.00% | 113.54% |
| Return on Assets (ROA) | -46.08% | -34.76% | -65.84% | -186.10% | -93.58% |
| Return on Equity (ROE) | -48.87% | -37.40% | -77.89% | -269.34% | -113.18% |
| Return on Capital Employed (ROCE) | -79.13% | -55.71% | -96.15% | -255.47% | -98.56% |
| Return on Invested Capital (ROIC) | -52.55% | -31.21% | -74.88% | -231.62% | -97.70% |
| Return on Tangible Assets | -46.08% | -34.76% | -65.84% | -316.42% | -123.88% |
| Earnings Yield | -9.29% | -6.84% | -6.41% | -28.62% | -68.19% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 39.49 | 8.15 |
| Payables Turnover | 0.37 | 0.11 | 0.04 | 4.41 | 0.28 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.32 | 0.13 | 8.14 | 0.80 |
| Asset Turnover | 0.00 | 0.01 | 0.00 | 0.07 | 0.03 |
| Working Capital Turnover Ratio | 0.00 | 0.01 | 0.00 | 0.09 | 0.06 |
| Cash Conversion Cycle | -983.15 | -3201.20 | -8356.18 | -73.60 | -1280.69 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 9.24 | 44.78 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 983.15 | 3201.20 | 8356.18 | 82.84 | 1325.47 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 9.24 | 44.78 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Free Cash Flow Per Share | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Dividend Paid and CapEx Coverage Ratio | -175.86 | -16.78 | -53.45 | -2355.54 | -11.07 |
| Capital Expenditure Coverage Ratio | -175.86 | -16.78 | -53.45 | -2355.54 | -11.07 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | -44.18 | -43.29 |
| Operating Cash Flow to Sales Ratio | 0.00 | -50.96 | -406.70 | -15.76 | -21.19 |
| Free Cash Flow Yield | -9.33% | -6.69% | -5.16% | -17.99% | -54.06% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -10.69 | -14.71 | -15.61 | -3.49 | -1.47 |
| Price-to-Sales (P/S) Ratio | 0.00 | 806.76 | 8029.79 | 87.64 | 42.73 |
| Price-to-Book (P/B) Ratio | 5.26 | 5.47 | 12.16 | 9.41 | 1.66 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -10.72 | -14.94 | -19.38 | -5.56 | -1.85 |
| Price-to-Operating Cash Flow Ratio | -10.78 | -15.83 | -19.74 | -5.56 | -2.02 |
| Price-to-Earnings Growth (PEG) Ratio | 0.73 | 0.55 | 0.45 | 0.39 | -0.56 |
| Enterprise Value Multiple | -5.42 | -8.01 | -11.65 | -2.94 | -0.85 |
| Enterprise Value | 60.12M | 88.84M | 123.79M | 30.54M | 6.72M |
| EV to EBITDA | -5.42 | -8.01 | -11.65 | -2.94 | -0.85 |
| EV to Sales | 0.00 | 653.25 | 7281.88 | 75.25 | 22.70 |
| EV to Free Cash Flow | -8.66 | -12.10 | -17.58 | -4.77 | -0.98 |
| EV to Operating Cash Flow | -8.71 | -12.82 | -17.90 | -4.77 | -1.07 |
| Tangible Book Value Per Share | 0.01 | 0.02 | 0.01 | 0.00 | 0.01 |
| Shareholders’ Equity Per Share | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.34 | 0.44 | 0.22 | 0.09 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 |
| Tax Burden | 0.66 | 1.00 | 1.00 | 0.91 | 1.00 |
| Interest Burden | 0.93 | 0.67 | 0.82 | 1.00 | 1.02 |
| Research & Development to Revenue | 0.00 | 47.95 | 396.20 | 9.82 | 8.78 |
| SG&A to Revenue | 0.00 | 22.50 | 163.00 | 7.65 | 9.44 |
| Stock-Based Compensation to Revenue | 0.00 | 6.21 | 61.69 | 2.13 | 1.97 |
| Income Quality | 1.00 | 0.92 | 0.79 | 0.63 | 0.73 |
Currency in AUD